{
    "clinical_study": {
        "@rank": "20120", 
        "arm_group": [
            {
                "arm_group_label": "sham transplantation of mesenchymal stem cells", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "autologous mesenchymal stem cell transplantation", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This project aims to evaluate the efficacy of autologous mesenchymal stem cell treatment to\n      preserve insulin production and beta-cell mass in recently diagnosed patients with type 1\n      diabetes mellitus. The hypothesis to be tested is that an increased number of circulating\n      mesenchymal stem cells will provide immune modulatory properties, and thereby stop the\n      immune process in islets causing progressive beta-cell death."
        }, 
        "brief_title": "Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study", 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  fasting C-peptide >0.12 nmol/l\n\n          -  within three weeks of diagnosis of type 1 diabetes\n\n        Exclusion Criteria:\n\n          -  body mass index (BMI) >30\n\n          -  unstable cardiovascular status incl. New York Heart Association (NYHA) class III/IV\n\n          -  patients with known or previous malignancy\n\n          -  active infections incl. serological evidence of infection with HIV, Treponema\n             pallidum, hepatitis B (patients with serology consistent with previous vaccination\n             and a history of vaccination are acceptable) or hepatitis C.\n\n          -  immune suppressive treatment\n\n          -  women being pregnant or nursing, or women physiologically capable of becoming\n             pregnant, unless they are using effective methods of contraception during study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057211", 
            "org_study_id": "AS Dnr2013/195"
        }, 
        "intervention": {
            "arm_group_label": "autologous mesenchymal stem cell transplantation", 
            "intervention_name": "autologous mesenchymal stem cell transplantation", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 5, 2014", 
        "location": {
            "contact": {
                "email": "torbjorn.linde@akademiska.se", 
                "last_name": "Torbj\u00f6rn Linde, Head of Department"
            }, 
            "facility": {
                "address": {
                    "city": "Uppsala", 
                    "country": "Sweden", 
                    "zip": "SE-75185"
                }, 
                "name": "Uppsala University Hospital"
            }, 
            "investigator": {
                "last_name": "Per-Ola Carlsson, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study", 
        "overall_official": {
            "affiliation": "Uppsala University Hospital", 
            "last_name": "Per-Ola Carlsson, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: The National Board of Health and Welfare"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2206-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.", 
            "time_frame": "\u2206-change will be assessed as a difference between  two years after transplantation/sham transplantation of mesenchymal stem cells when compared to before transplantation/sham transplantation, i.e. at time 0."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057211"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Uppsala University Hospital", 
            "investigator_full_name": "Per-Ola Carlsson", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Uppsala University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Uppsala University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}